Harvard Apparatus Regenerative Technology Welcomes New Director
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Holliston, MA -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a pioneering clinical-stage biotechnology company focused on organ regeneration technology, has announced the appointment of Mao Zhang as an independent director to its Board of Directors. This strategic addition aims to enhance the company's capabilities in business innovation, strategy, and finance.
Mao Zhang, who serves as the Founder and Chief Executive Officer of StellarS Capital, brings over 15 years of experience in the financial markets, specialized in hedge funds and private equity. His career began in 2007 with Magnetar Capital where he led their Asian business operations. Mr. Zhang holds a Bachelor of Science degree from the University of Pennsylvania.
A Strong Addition to the Board
“We are pleased to welcome Mao Zhang to the Harvard Apparatus Regenerative Technology Board,” stated Jerry He, Chairman of Harvard Apparatus Regenerative Technology. “Mao's extensive business and investment experience will play a crucial role in our mission to address unmet patient needs. His appointment comes at a time of tremendous opportunity for growth within the company.”
In his remarks, Mr. Zhang expressed enthusiasm about joining the Board, stating, “I am very pleased to be joining the Board of Directors for Harvard Apparatus Regenerative Technology at this exciting stage of its clinical development. The company is advancing novel cell therapies that possess the potential to fundamentally change the lives of patients through organ regeneration. I look forward to aligning my efforts with Harvard Apparatus Regenerative Technology’s financial and strategic objectives.”
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, Inc. operates at the forefront of regenerative medicine, developing treatments for gastrointestinal disorders and other organ dysfunctions that arise due to cancer, trauma, or congenital defects. The company's pioneering technology harnesses a proprietary cell-therapy platform utilizing a patient’s own stem cells to regenerate and restore functionality in damaged organs. This innovative approach not only presents a potential next-generation solution for restoring organ function but also mitigates the need for donor organs or permanent artificial implants, enhancing patient outcomes significantly.
In 2017, Harvard Apparatus Regenerative Technology achieved a historic milestone by conducting the world’s first successful regeneration of the esophagus in a patient suffering from esophageal cancer. This pivotal surgery was executed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic, with results published in the Journal of Thoracic Oncology Clinical and Research Reports.
Noteworthy Achievements and Market Position
The company currently boasts 15 U.S. patents along with various patents granted in key international markets including China, Japan, and Europe. Additionally, Harvard Apparatus Regenerative Technology has obtained two orphan-drug designations in the United States, which can offer up to seven years of market exclusivity after FDA approval, as well as an orphan drug designation from the European Medicines Agency, allowing for ten years of market exclusivity in Europe post-approval.
Investor Relations Contact
For further inquiries, Joseph Damasio, Chief Financial Officer, is available at 774-233-7330 or via email at jdamasio@hregen.com.
Frequently Asked Questions
What is the role of Mao Zhang in Harvard Apparatus Regenerative Technology?
Mao Zhang has been appointed as an independent director to the Board of Directors, focusing on enhancing business innovation, strategic direction, and financial oversight.
What technology does Harvard Apparatus Regenerative Technology develop?
The company develops regenerative medicine treatments targeting disorders of the gastrointestinal system and other organs, primarily using patient-derived stem cells.
What notable achievement does Harvard Apparatus Regenerative Technology have?
The company conducted the first successful esophagus regeneration surgery in 2017, marking a significant advancement in organ regeneration technology.
How many patents does Harvard Apparatus Regenerative Technology hold?
Harvard Apparatus Regenerative Technology holds 15 issued patents in the U.S. and several issued patents in international markets.
What is the significance of orphan-drug designations for the company?
Orphan-drug designations offer market exclusivity that can significantly enhance the company’s competitive position and financial opportunities following regulatory approvals.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.